Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Despite advances in clinical therapy, metastasis remains the leading cause of death in breast cancer patients. Mutations in mitochondrial DNA, including those affecting complex I and oxidative phosphorylation, are found in breast tumors and could facilitate metastasis. This study identifies mitochondrial complex I as critical for defining an aggressive phenotype in breast cancer cells. Specific enhancement of mitochondrial complex I activity inhibited tumor growth and metastasis through regulation of the tumor cell NAD+/NADH redox balance, mTORC1 activity, and autophagy. Conversely, nonlethal reduction of NAD+ levels by interfering with nicotinamide phosphoribosyltransferase expression rendered tumor cells more aggressive and increased metastasis. The results translate into a new therapeutic strategy: enhancement of the NAD+/NADH balance through treatment with NAD+ precursors inhibited metastasis in xenograft models, increased animal survival, and strongly interfered with oncogene-driven breast cancer progression in the MMTV-PyMT mouse model. Thus, aberration in mitochondrial complex I NADH dehydrogenase activity can profoundly enhance the aggressiveness of human breast cancer cells, while therapeutic normalization of the NAD+/NADH balance can inhibit metastasis and prevent disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 1×
“One of the main regulators of autophagy is mTORC1, which links tumor growth and metabolism (46).”
Autophagy as a Regulated Pathway of Cellular Degradation
Klionsky, D. J., & Emr, S. D. (2000) · Science · doi:10.1126/science.290.5497.1717 · Cited by 3,608
On Respiratory Impairment in Cancer Cells
Warburg, O. (1956) · Science · doi:10.1126/science.124.3215.269 · Cited by 3,468
Wallace, D. C. (2005) · Annual Review of Genetics · doi:10.1146/annurev.genet.39.110304.095751 · Cited by 3,185
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
Klionsky, D. J., Abeliovich, H., Agostinis, P., Agrawal, D. K., Aliev, G., Askew, D. S., Baba, M., Baehrecke, E. H., Bahr, B. A., Ballabio, A., et al. (2008) · Autophagy · doi:10.4161/auto.5338 · Cited by 2,230
Autophagy Suppresses Tumorigenesis through Elimination of p62
Mathew, R., Karp, C. M., Beaudoin, B., Vuong, N., Chen, G., Chen, H.-Y., Bray, K., Reddy, A., Bhanot, G., Gelinas, C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.048 · Cited by 1,719
Cancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2013 · Cited by 1,699
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.954 · Cited by 1,631
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
Research works printed but not linked: 3
- Parrella, 2001, Cancer Res., 61, 7623
- Hasmann, 2003, Cancer Res., 63, 7436
- Brinkley, 1980, Cancer Res., 40, 3118
Cited by
Birsoy, K., Wang, T., Chen, W. W., Freinkman, E., Abu-Remaileh, M., & Sabatini, D. M. (2015) · Cell · doi:10.1016/j.cell.2015.07.016 · Cited by 1,388
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
“Currently it is known that, certain cancer cells may also actively use OXPHOS or a combination of OXPHOS and glycolysis for ATP production (45, 46).”
BackgroundTumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism
Zhao, H., Yang, L., Baddour, J., Achreja, A., Bernard, V., Moss, T., Marini, J. C., Tudawe, T., Seviour, E. G., San Lucas, F. A., et al. (2016) · eLife · doi:10.7554/elife.10250 · Cited by 927
“Although recent studies (Ishikawa et al., 2008; Santidrian et al., 2013), including our own (Yang et al.”
ResultGlutaminolysis: A Hallmark of Cancer Metabolism
Yang, L., Venneti, S., & Nagrath, D. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044546 · Cited by 859
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides
Birsoy, K., Possemato, R., Lorbeer, F. K., Bayraktar, E. C., Thiru, P., Yucel, B., Wang, T., Chen, W. W., Clish, C. B., & Sabatini, D. M. (2014) · Nature · doi:10.1038/nature13110 · Cited by 710
Defining the Hallmarks of Metastasis
Welch, D. R., & Hurst, D. R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0458 · Cited by 700
How the Warburg effect supports aggressiveness and drug resistance of cancer cells?
Icard, P., Shulman, S., Farhat, D., Steyaert, J.-M., Alifano, M., & Lincet, H. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.001 · Cited by 643
Mitochondria as playmakers of apoptosis, autophagy and senescence
Abate, M., Festa, A., Falco, M., Lombardi, A., Luce, A., Grimaldi, A., Zappavigna, S., Sperlongano, P., Irace, C., Caraglia, M., et al. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.022 · Cited by 545
Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: Focusing on mitochondria
Zhong, H., & Yin, H. (2015) · Redox Biology · doi:10.1016/j.redox.2014.12.011 · Cited by 536
Mitochondrial Dysfunction in Cancer
Boland, M. L., Chourasia, A. H., & Macleod, K. F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00292 · Cited by 489
Mullen, A. R., Hu, Z., Shi, X., Jiang, L., Boroughs, L. K., Kovacs, Z., Boriack, R., Rakheja, D., Sullivan, L. B., Linehan, W. M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.037 · Cited by 337
“Exposure to hypoxia ( 1% O2) has also been demonstrated to reduce the cellular NAD+/ NADH ratio (Santidrian et al., 2013) and to favor modest 2HG accumulation in cultured cells (Wise et al., 2011), although these levels were below those noted in gliomas expressing 2HG-producing mutant alleles of…”
BackgroundMitochondrial Respiration Controls Lysosomal Function during Inflammatory T Cell Responses
Baixauli, F., Acín-Pérez, R., Villarroya-Beltrí, C., Mazzeo, C., Nuñez-Andrade, N., Gabandé-Rodriguez, E., Ledesma, M. D., Blázquez, A., Martin, M. A., Falcón-Pérez, J. M., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.07.020 · Cited by 326
Mitochondria and cancer chemoresistance
Guerra, F., Arbini, A. A., & Moro, L. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.01.012 · Cited by 323
Goodson, W. H., Lowe, L., Carpenter, D. O., Gilbertson, M., Manaf Ali, A., Lopez de Cerain Salsamendi, A., Lasfar, A., Carnero, A., Azqueta, A., Amedei, A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv039 · Cited by 322
Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis
Lehuédé, C., Dupuy, F., Rabinovitch, R., Jones, R. G., & Siegel, P. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0266 · Cited by 289
Parkin and mitophagy in cancer
Bernardini, J. P., Lazarou, M., & Dewson, G. (2017) · Oncogene · doi:10.1038/onc.2016.302 · Cited by 281
Jia, D., Park, J., Jung, K., Levine, H., & Kaipparettu, B. (2018) · Cells · doi:10.3390/cells7030021 · Cited by 270
Ciavardelli, D., Rossi, C., Barcaroli, D., Volpe, S., Consalvo, A., Zucchelli, M., De Cola, A., Scavo, E., Carollo, R., D'Agostino, D., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.285 · Cited by 269
Metabolic adaptation in hypoxia and cancer
Paredes, F., Williams, H. C., & San Martin, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.020 · Cited by 259
Airhart, S. E., Shireman, L. M., Risler, L. J., Anderson, G. D., Nagana Gowda, G. A., Raftery, D., Tian, R., Shen, D. D., & O’Brien, K. D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186459 · Cited by 259
Mick, E., Titov, D. V., Skinner, O. S., Sharma, R., Jourdain, A. A., & Mootha, V. K. (2020) · eLife · doi:10.7554/elife.49178 · Cited by 249
“It provides the driving force for ATP synthesis by oxidative phosphorylation (OXPHOS) (Mitchell, 1961; Mitchell, 2011), maintains redox balance of cofactor pairs (NADH:NAD, CoQH2:CoQ) that are coupled to hundreds of cellular reactions (Williamson et al., 1967; Ying, 2008; Santidrian et al., 2013; Titov et al., 2016; X…”
BackgroundATP-Dependent Lon Protease Controls Tumor Bioenergetics by Reprogramming Mitochondrial Activity
Quirós, P. M., Español, Y., Acín-Pérez, R., Rodríguez, F., Bárcena, C., Watanabe, K., Calvo, E., Loureiro, M., Fernández-García, M. S., Fueyo, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.018 · Cited by 233
“Moreover, Lon protease overexpression reduces the use of NADH equivalents and the respiration through CI, which is frequently mutated and inactivated in tumor cell lines (Santidrian et al., 2013).”
BackgroundGanapathy-Kanniappan, S. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1556578 · Cited by 216
Bonora, M., & Pinton, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00302 · Cited by 208
“reduces breast cancer tumor formation and metastasis (126).”
BackgroundSources and implications of NADH/NAD+ redox imbalance in diabetes and its complications
Yan, L.-J., Wu, J., Jin, Z., & Zheng, H. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s106087 · Cited by 198
Chaube, B., Malvi, P., Singh, S. V., Mohammad, N., Meena, A. S., & Bhat, M. K. (2015) · Oncotarget · doi:10.18632/oncotarget.6134 · Cited by 80
“Consequences of inhibiting complex I on growth of cancer cells are not clearly understood though, reports suggest that complex I inhibition leads to cellular transformation and enhances cell growth [14-18].”
BackgroundContribution of Mitochondrial DNA Variation to Chronic Disease in East Asian Populations
Sun, D., Wei, Y., Zheng, H.-X., Jin, L., & Wang, J. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00128 · Cited by 21
Metadata
- Authors
- Santidrian, A. F., Matsuno-Yagi, A., Ritland, M., Seo, B. B., LeBoeuf, S. E., Gay, L. J., Yagi, T., & Felding-Habermann, B.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-02-15
- Volume
- 123
- Issue
- 3
- Pages
- 1068-1081
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2124276356
- Cited by
- 433
- References
- 65
- FWCI
- 11.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.